source
- Novartis IL-6 antibody pacibekitug cuts inflammation markers in Phase 2 studyA Phase 2 trial called TRANQUILITY showed that pacibekitug, an IL-6‑targeting antibody acquired by Novartis, reduced several biomarkers of inflammation in participants. The reductions were sustain…
- Novartis launches Phase 3 trial of IL-6 antibody to test cardiovascular benefit despite Novo's setbackNovartis announced it will begin a Phase 3 study evaluating its anti-IL-6 monoclonal antibody in patients at high cardiovascular risk. The trial aims to determine whether reducing inflammation thr…